1. Home
  2. NHS vs ACIU Comparison

NHS vs ACIU Comparison

Compare NHS & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuberger Berman High Yield Strategies Fund

NHS

Neuberger Berman High Yield Strategies Fund

HOLD

Current Price

$6.08

Market Cap

259.9M

Sector

Finance

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.36

Market Cap

221.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NHS
ACIU
Founded
2003
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
259.9M
221.9M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
NHS
ACIU
Price
$6.08
$2.36
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
164.8K
171.9K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
13.44%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$706.75
Revenue Next Year
N/A
$321.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.97
$2.03
52 Week High
$7.75
$4.00

Technical Indicators

Market Signals
Indicator
NHS
ACIU
Relative Strength Index (RSI) 45.62 49.03
Support Level $6.06 $2.13
Resistance Level $6.30 $2.41
Average True Range (ATR) 0.06 0.11
MACD 0.01 0.01
Stochastic Oscillator 56.88 65.31

Price Performance

Historical Comparison
NHS
ACIU

About NHS Neuberger Berman High Yield Strategies Fund

Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: